300006.SZ Stock Analysis
30
Uncovered
Chongqing Lummy Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and sale of pharmaceuticals. The company is headquartered in Chongqing, Chongqing and currently employs 935 full-time employees. The company went IPO on 2009-10-30. The Company’s medicines consist of anti-infection medicines, special medicines, infusion, Chinese patent drugs and herbal decoction pieces. The firm's main products include carbon nanoparticles suspension injection, omeprazole enteric capsules, mycobacterium phlei F.U.36 injection, levofloxacin hydrochloride and tranexamic acid and sodium chloride injection, among others. The firm distributes its products in domestic market.